LETROZOLE

Post-LOESM

letrozole

ANDAORALTABLET
Approved
Nov 2018
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

Aromatase Inhibitors

Pharmacologic Class:

Aromatase Inhibitor

Clinical Trials (5)

NCT06790693Phase 3Recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

Started Apr 2025
450 enrolled
Breast Cancer
NCT06760637Phase 3Recruiting

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

Started Jan 2025
1,020 enrolled
Breast Cancer
NCT06366347Phase 2Recruiting

ALPINE: Maintenance Letrozole/Abemaciclib

Started Sep 2024
32 enrolled
Endometrial CancerRecurrent Endometrial CancerTP53
NCT06465368Phase 2Completed

A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause

Started Jul 2024
121 enrolled
Breast Cancer
NCT05872204Phase 2Recruiting

Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer

Started Nov 2023
100 enrolled
Low Grade Serous Ovarian CarcinomaAdult Type Granulosa Cell Tumor